期刊
DRUG DISCOVERY TODAY
卷 27, 期 1, 页码 347-353出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.drudis.2021.09.014
关键词
Health Technology Assessment; Early scienti fic advice; Drug development; Reimbursement; Regulator; Parallel scienti fic advice
There is a growing trend for pharmaceutical companies to seek scientific advice on drug development from a Health Technology Assessment (HTA) perspective, to improve the efficiency of their studies and support positive HTA recommendations. This study evaluates pharmaceutical companies' strategies and practices for seeking HTA-related scientific advice based on information collected directly from companies.
There is a growing trend for pharmaceutical companies to seek scientific advice on drug development from a Health Technology Assessment (HTA) perspective, to improve the efficiency of their studies, enable better trial design, and support the goals of positive HTA recommendation for reimbursement. This study uses information collected directly from companies on individual products to assess their strategies and practices for seeking HTA-related scientific advice in terms of which stakeholders to engage and for what purpose, when to seek scientific advice, and whether to implement that advice within global clinical development.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据